Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

The Role of Primary Tumor Treatment and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer.

Gupta A, Pugh TJ, Lam E, Sheridan AD, Nath S.

Oncology (Williston Park). 2019 May 14;33(5):187-91. No abstract available.

2.

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.

Kim J, Park JS, Ham WS.

Investig Clin Urol. 2017 Sep;58(5):307-316. doi: 10.4111/icu.2017.58.5.307. Epub 2017 Aug 8. Review.

3.

Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.

Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W, Joniau S.

Eur Urol Oncol. 2019 Mar;2(2):174-188. doi: 10.1016/j.euo.2018.09.005. Epub 2018 Oct 9. Review.

PMID:
31017094
4.

[Surgical treatment of local disease in metastatic prostate cancer.]

Gaya JM, Huguet J, Breda A, Palou J.

Arch Esp Urol. 2018 Mar;71(3):288-297. Review. Spanish.

PMID:
29633950
5.

Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.

Kothari G, Ost P, Cheung P, Blanchard P, Tree AC, van As NJ, Lo SS, Moghanaki D, Loblaw A, Siva S.

Curr Oncol Rep. 2019 Mar 27;21(5):43. doi: 10.1007/s11912-019-0791-5. Review.

PMID:
30919165
6.

The role of hormone therapy and chemotherapy in oligometastatic prostate cancer.

Miura Y, Horie S.

ESMO Open. 2019 Mar 12;4(Suppl 1):e000471. doi: 10.1136/esmoopen-2018-000471. eCollection 2019. Review.

7.

Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer.

Clement JM, Sweeney CJ.

J Oncol Pract. 2017 Jan;13(1):9-18. doi: 10.1200/JOP.2016.018523. Epub 2017 Jan 3. Review.

PMID:
28045610
8.

Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.

Tsumura H, Ishiyama H, Tabata KI, Sekiguchi A, Kawakami S, Satoh T, Kitano M, Iwamura M.

Prostate. 2019 Apr;79(5):506-514. doi: 10.1002/pros.23757. Epub 2018 Dec 26.

PMID:
30585345
9.

A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?

Slaoui A, Albisinni S, Aoun F, Assenmacher G, Al Hajj Obeid W, Diamand R, Regragui S, Touzani A, Bakar A, Mesfioui A, Karmouni T, Ameur A, Elkhader K, Koutani A, Ibnattya A, Roumeguere T, Peltier A.

World J Urol. 2019 Jan 31. doi: 10.1007/s00345-019-02652-7. [Epub ahead of print]

PMID:
30706122
10.

Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.

Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, Weichselbaum RR, Kao J, Urbanic JJ, Milano MT, Chmura SJ, Salama JK.

PLoS One. 2018 Apr 12;13(4):e0195149. doi: 10.1371/journal.pone.0195149. eCollection 2018.

11.

[Oligometastatic prostate cancer. concept and implications.]

Carrasco Valiente J, Ruiz García JM, Requena Tapia MJ.

Arch Esp Urol. 2018 Mar;71(3):239-246. Review. Spanish.

PMID:
29633944
12.

Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.

Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, Beckers A, Fonteyne V, Van der Eecken K, De Bruycker A, Paul J, Gramme P, Ost P.

World J Urol. 2018 Dec 21. doi: 10.1007/s00345-018-2609-8. [Epub ahead of print]

PMID:
30578441
13.

Modeling growth kinetics and statistical distribution of oligometastases.

Withers HR, Lee SP.

Semin Radiat Oncol. 2006 Apr;16(2):111-9. Review.

PMID:
16564446
14.

What Is Oligometastatic Prostate Cancer?

Fraser M, Koontz B, Emmenegger U, De Meerleer G, Khoo V, Feng F, Corcoran NM, Hovens CM, Tran PT, Ost P, Boutros PC; GAP6 Consortium.

Eur Urol Focus. 2019 Mar;5(2):159-161. doi: 10.1016/j.euf.2018.12.009. Epub 2019 Jan 12. Review.

PMID:
30642810
15.

Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.

De Bleser E, Tran PT, Ost P.

Curr Opin Urol. 2017 Nov;27(6):587-595. doi: 10.1097/MOU.0000000000000441. Review.

PMID:
28816714
16.

The Role of Local Therapy for Oligometastatic Prostate Cancer: Should We Expect a Cure?

Nair R, Lamb BW, Geurts N, Alghazo O, Lam W, Lawrentschuk N, Murphy DG.

Urol Clin North Am. 2017 Nov;44(4):623-633. doi: 10.1016/j.ucl.2017.07.013. Review.

PMID:
29107278
17.

Oligometastases in prostate cancer: Ablative treatment.

Palacios-Eito A, Béjar-Luque A, Rodríguez-Liñán M, García-Cabezas S.

World J Clin Oncol. 2019 Feb 24;10(2):38-51. doi: 10.5306/wjco.v10.i2.38. Review.

18.

Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.

Joice GA, Rowe SP, Pienta KJ, Gorin MA.

Curr Opin Urol. 2017 Nov;27(6):533-541. doi: 10.1097/MOU.0000000000000449. Review.

PMID:
28863016
19.

OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.

Supiot S, Rio E, Pacteau V, Mauboussin MH, Campion L, Pein F.

BMC Cancer. 2015 Sep 25;15:646. doi: 10.1186/s12885-015-1579-0.

20.

Oligometastatic prostate cancer: The game is afoot.

Lancia A, Zilli T, Achard V, Dirix P, Everaerts W, Gomez-Iturriaga A, Ingrosso G, Liefhooghe N, Miralbell R, Siva S, Van der Eecken K, Ost P.

Cancer Treat Rev. 2019 Feb;73:84-90. doi: 10.1016/j.ctrv.2019.01.005. Epub 2019 Jan 17. Review.

PMID:
30684842

Supplemental Content

Support Center